Our Venture Partners are important team members who help evaluate and provide advice on potential investments. The Venture Partners also serve as independent board members of select portfolio companies and provide, when appropriate, consulting, management and advisory services to our companies on a case-by-case basis.
Jeffrey J. Collinson
Jeff has been investing as a venture capitalist since 1972, when he joined the first Schroder venture capital operation. He has invested in the healthcare area since 1981, when he became President of the Schroder Ventures US operation.
In 1990, he founded Collinson Howe Venture Partners with Tim Howe as an independent entity that continued to manage the Schroder Ventures funds through to their conclusion in 2001. In 1997, he co-founded CHL Medical Partners.
Jeff has been actively involved in founding numerous healthcare companies including Celgene Corporation (NASDAQ: CELG), Incyte Pharmaceuticals, Inc. (NASDAQ: INCY), SemperCare, Inc. (sold to Select Medical, NYSE: SEM), Ascend Health Corporation (sold to Universal Health Services, NYSE: UHS), Intensiva, Inc. (IPO then acquired by Select Medical, NYSE: SEM), and American Renal Associates.
Prior to joining Schroder, Jeff worked for Baxter International, Inc., in the areas of finance and corporate development. Jeff has served on the boards of over thirty portfolio companies, many of which are now public.
Jeff is a graduate of Yale University and the Harvard Business School.
David has over 30 years of success as a healthcare executive, entrepreneur, and investor. He has co-founded several healthcare services ventures, including Community Health Systems (NYSE: CHS) (1986) – a chain of acute care hospitals now totaling 135 in 29 states, Intensiva Healthcare, Inc. (1994) – long-term acute care hospitals, Odyssey Healthcare (1995) – a home hospice provider, SemperCare Inc. (1999) – long term acute care hospitals, and Ascend Health Corporation (2004) — psychiatric hospitals.
Prior to the founding of CHS, where he served as Vice Chairman, David was a Regional Vice President of Hospital Affiliates managing 15 hospitals. Before that, he was Director, Hospital Administration at Ohio State University Medical Center.
David holds a B.A. from Ohio State University and a Masters of Health Administration from University of Southern California.
Myles D. Greenberg, M.D.
Myles Is Chief Development Officer at IntegraMed, Inc. Prior to joining IntegraMed in 2015, Myles was a Partner at CHL Medical Partners where he led numerous investments in start-up and early-stage healthcare services and medical device companies including Vascular Pathways, Inc., (sold to C.R. Bard), Millennium Pharmacy Systems, Inc. (sold to Pharmerica), Mevion Medical Systems, Inc., and CareWell Urgent Care Centers of New England, where he was the founder and lead director.
Previously, Myles served on the faculty and as Assistant Clinical Director of the Emergency Department of Beth Israel Deaconess Medical Center / Harvard Medical School where he managed many of the clinical, educational, and administrative functions.
Myles is a graduate of the University of Pennsylvania School of Engineering and Applied Science, Yale University School of Medicine, and Harvard Business School. He completed residency training in emergency medicine at the University of Pittsburgh and is board certified by the American Board of Emergency Medicine.
Gregory M. Weinhoff, M.D.
Greg is Chief Financial Officer at Axovant Sciences Ltd. Prior to joining Axovant in 2015, Greg was a Partner at CHL Medical Partners where he was the founding investor of several CHL companies where he played a key role starting the companies, hiring the management teams, and developing the companies’ strategic plans, including Fidelis SeniorCare, Inc., Ella Health, Inc., and Amicus Therapeutics (NASDAQ: FOLD).
Greg is a graduate of Harvard College, Harvard Medical School and Harvard Business School, where he was a Baker Scholar.